Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study

Diabetes, Obesity and Metabolism

Volumn 15, Issue 5, 2013, Pages 403-409

  Wilding, J P H ^a   Ferrannini, E ^b   Fonseca, V A ^c   Wilpshaar, W ^d   Dhanjal, P ^d   Houzer, A ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF PISA   (Italy)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d Astellas Pharma Global Development   (Netherlands)

Author keywords

Antidiabetic drugs; Clinical trial; Dose finding; Ipragliflozin; SGLT2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; IPRAGLIFLOZIN; METFORMIN;

ADULT; ALOPECIA; ARTICLE; BODY MASS; CALCULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; URTICARIA; VITAL SIGN; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84876344111     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12038     Document Type: Article

References (30)

1. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012; 35(Suppl. 1): S11-S63.
2. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63-71.
3. Ferrannini E, Solini A. 2012. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 8: 495-502.
4. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
5. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377-385.
6. Tahara A, Kurosaki E, Yokono M et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs. Arch Pharmacol 2012; 385: 423-436.
7. Kadokura T, Saito M, Utsuno A, Kazuta K, Yoshida S, Kawasaki S. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int 2011; 2: 172-182.
8. Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 2011; 31: 839-851.
9. Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Kageyama S. ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus [abstract 75-OR]. Presented at the 70th American Diabetes Association (ADA) Meeting, June 25-29, 2010; Orlando, FL, USA.
10. Kashiwagi A, Takinami Y, Kazuta K, Yoshida S, Utsuno A. Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study [abstract OR149]. Presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting, September 12-16, 2011, Lisbon, Portugal.
11. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011; 13: 1219-1227.
12. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 34-42.
13. Gerich JE, Bastien A. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol 2011; 4: 669-683.
14. Freijer J, Krauwinkel WJ, Kadokura T, Zhang W, Kaibara A, Smulders R. PK/PD model for ASP1941, a novel SGLT2 inhibitor, characterizes exposure-urinary glucose excretion relationship in healthy subjects and type 2 diabetes mellitus patients. J Am Assoc Pharm Sci 2010; 12(Suppl. 1): S13-S61.
15. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
16. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72.
17. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res 2006; 15: 481-491.
18. American Diabetes Association. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005; 28: 1245-1249.
19. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
20. Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
21. Bolinder J, Ljunggren Ö, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
22. Dupont AG. The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years. Cardiovasc Drugs Ther 1993; 7(Suppl. 1): 55-62.
23. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-884.
24. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9: 551-559.
25. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
26. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
27. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
28. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
29. Wilding JP, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-415.
30. Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Ball G, Klasen S 2011. Active-controlled dose-finding study of efficacy, safety, and tolerability of multiple doses ipragliflozin in type 2 diabetes patients. [abstract O-0592]. Presented at the IDF World Diabetes Congress Biennial Meeting. December 4-8, Dubai, United Arab Emirates.